Kendall Feia’s research while affiliated with University of Minnesota, Duluth and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (5)


Validity of Midday Total Testosterone Levels in Older Men with Erectile Dysfunction
  • Article

July 2014

·

116 Reads

·

23 Citations

The Journal of Urology

·

·

·

[...]

·

Introduction: Based on studies demonstrating the circadian rhythmicity of testosterone levels, the optimal time of day to draw total testosterone (TT) in men has classically been reported as between 8 and 11 AM. However, further studies have demonstrated that the circadian rhythmicity of testosterone levels becomes blunted with age. Methods: Charts of 2,569 men presenting with erectile dysfunction (ED), were retrospectively reviewed for TT and draw times and were compared by age group. Men were grouped to: less than 40, and then by 5 year groupings. TT was analyzed for variability over the most common draw time hours (7 AM – 2 PM). Results: The mean TT for 7-9 AM versus 9 AM-2 PM were both clinically and statistically different only for men in the age groups of < 40 and 40-44, with mean TT differences of 207 ng/dL [95% CI 98-315 p = 0.0004], and 149 ng/dL [95% CI 36-262 p = 0.01] respectively. All other groupings did not demonstrate both a clinically and statistically significant difference between those time periods. Conclusion: A TT level in men with ED who are younger than 45 years should be drawn as close to 7 AM as possible as a statistically and a clinically relevant drop in testosterone levels will occur over the course of the day. Men older than age 45 years with ED can have their TT drawn at any time before 2 PM without fear of misleading results.


Alfuzosin to Relieve Ureteral Stent Discomfort: A Prospective, Randomized, Placebo Controlled Study

November 2008

·

103 Reads

·

142 Citations

The Journal of Urology

We assessed the impact of alfuzosin on ureteral stent discomfort. A total of 66 patients scheduled for unilateral retrograde ureteroscopy with stent placement provided consent for the study. Patients were randomized between placebo and the study medication, and investigators and patients were blinded to the randomization scheme. To evaluate pain and urinary symptoms patients were asked to complete the Ureteral Stent Symptom Questionnaire (Stone Management Unit, Southmead Hospital, Westbury-on-Trym, United Kingdom) before ureteroscopy and 3 days after the procedure to minimize the confounding impact of procedural discomfort due to surgery. Patients were also asked to maintain a use log of pain medication each day that the ureteral stent was in place. Procedure outcome and complications were recorded, as were patient study medication use and vital health information before the procedure and at the time of stent removal. Statistical analysis was performed using the Student t, chi-square and Wilcoxon rank sum tests, as appropriate, with p <0.05 considered significant. Of 66 patients who provided consent 55 successfully completed the study. In 3 of the 11 failed cases surgery was not done due to spontaneous stone passage, surgery was performed in 3 but no ureteral stent was placed, 4 were excluded from study after obtaining consent due to exclusion criteria and 1 was voluntarily removed from study after obtaining consent but before surgery. Regarding stent type, procedure complications and baseline questionnaire results there were no significant differences between the placebo and alfuzosin arms. When comparing post-procedure questionnaire results, patients in the alfuzosin arm reported less overall pain in the kidney/back/loin area and less pain in the kidney area while passing urine (p = 0.017 and 0.007, respectively). Men in the alfuzosin arm also reported a lesser incidence of excessive urination (p = 0.040). When comparing changes from baseline questionnaire results, the alfuzosin arm experienced a decrease in kidney pain during sleep (p = 0.017), less frequent use of painkillers to control kidney pain (p = 0.020) and a decrease in how much kidney associated pain interfered with life (p = 0.045). There was no significant difference in the amount of narcotics used per day, as reported in patient medication logs. Alfuzosin improves the patient discomfort associated with ureteral stents by decreasing urinary symptoms and kidney pain but it does not affect the amount of narcotics that patients use while the stent is in place.


Alfuzosin Stone Expulsion Therapy for Distal Ureteral Calculi: A Double-Blind, Placebo Controlled Study

June 2008

·

42 Reads

·

113 Citations

The Journal of Urology

We evaluated the efficacy of alfuzosin as medical expulsive therapy for distal ureteral stone passage. A total of 76 patients with a distal ureteral calculus provided consent for the study. Patients were randomized between placebo and study medication, and investigators and patients were blinded to the randomization scheme. Followup was done on a weekly basis and continued until the patient was rendered stone-free. The patient blood pressure, discomfort level, stone position on imaging, number of remaining pills and any adverse events were assessed. Statistical analysis was performed with the Student t test with p <0.05 considered significant. The overall spontaneous stone passage rate was 75%, including 77.1% for placebo and 73.5% for alfuzosin (p = 0.83). Mean +/- SD time needed to pass the stone was 8.54 +/- 6.99 days for placebo vs 5.19 +/- 4.82 days for alfuzosin. (p = 0.003). There was no difference in the size or volume of stones that passed spontaneously between the placebo and alfuzosin arms, as measured on baseline computerized tomography (4.08 +/- 1.17 and 3.83 +/- 0.95 mm, p = 0.46) and by a digital caliper after stone expulsion (3.86 +/- 1.76 and 3.91 +/- 1.06 mm, respectively, p = 0.57). When comparing the improvement from the baseline pain score, the alfuzosin arm experienced a greater decrease in pain score in the days after the initial emergency department visit to the date of stone passage (p = 0.0005). Alfuzosin improves the patient discomfort associated with stone passage and decreases the time to distal ureteral stone passage but it does not increase the rate of spontaneous stone passage.


Prevalence of Androgen Deficiency in Men with Erectile Dysfunction

May 2008

·

17 Reads

·

84 Citations

Urology

Erectile dysfunction (ED) and androgen deficiency in aging men are two separate clinical entities that often overlap. Controversy exists regarding the most appropriate total testosterone level that defines androgen deficiency in aging men, and its prevalence in men with ED is still uncertain. We evaluated the prevalence and risk factors of low and low-normal testosterone levels in men presenting for an initial ED evaluation. The computerized charts from 1987 to 2002 of 2794 men aged 25 to 80 years and presenting with a primary complaint of ED who also had serum total testosterone levels measured were retrospectively reviewed. Multiple testosterone level cutpoints and a linear regression model (including age, diabetes, cholesterol, anemia, creatinine, and prostate-specific antigen) were used to analyze the factors that correlated with hypogonadism. The prevalence of androgen deficiency was 7%, 23%, 33%, and 47% for testosterone levels of less than 200, less than 300, less than 346, and less than 400 ng/dL, respectively. An abrupt increase in hypogonadism prevalence occurred in men aged 45 to 50, beyond which a plateau of prevalence was maintained until older than 80 years of age. Age, the presence of uncontrolled diabetes, high total cholesterol, and anemia all correlated with significantly decreased testosterone levels in men with ED. The prostate-specific antigen level and creatinine did not affect the testosterone levels. Androgen deficiency was quite common in men presenting with ED and correlated significantly with age, uncontrolled diabetes, hypercholesteremia, and anemia. Although additional prospective studies evaluating the effect of testosterone supplementation in this population are needed, clinicians, including urologists, should be keenly aware of the large overlap of patients with ED who might also have the entity, androgen deficiency in the aging male.


Citations (4)


... Free testosterone was determined by calculation (26). Blood was sampled between 6:00 am and 9:00 am to limit the potential confounding effects of diurnal variation of total testosterone in young men (27). ...

Reference:

Effects of Testosterone on Mixed-Muscle Protein Synthesis and Proteome Dynamics During Energy Deficit
Validity of Midday Total Testosterone Levels in Older Men with Erectile Dysfunction
  • Citing Article
  • July 2014

The Journal of Urology

... Further review excluded 10 articles as they were irrelevant to the analysis: 3 for cited improper interventions and 7 for improper outcomes. Finally, 16 RCTs, including 1865 patients, were identified as relevant for the current study and selected for the meta-analysis [10,[16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]. Figure 1 shows the study flow chart. total of 26 articles were selected for full-text evaluation. ...

Alfuzosin to Relieve Ureteral Stent Discomfort: A Prospective, Randomized, Placebo Controlled Study
  • Citing Article
  • November 2008

The Journal of Urology

... In 2002, approximately 37.5% of Thai men aged 40-70 years had this condition, amounting to 3 million people across the country. 1 One study in 2006 found that 38.5% of Asian people had this condition and that the prevalence of ED was rising with increasing aging. 2 There are many contributing factors to ED. One of the most common concomitant endocrine conditions is hypogonadism or testosterone deficiency, which is found in 33% of patients with ED. 3 The causes of ED and testosterone deficiency are usually multifactorial and share the same risk factors as cardiovascular disease. 4 Signs and symptoms of testosterone deficiency are decreased libido, ED, fatigue, anemia, decreased bone density, and depression. ...

Prevalence of Androgen Deficiency in Men with Erectile Dysfunction
  • Citing Article
  • May 2008

Urology

... 4,5,6 For a substantial period, these pharmaceutical agents have been employed in the context of medical expulsive therapy. [7][8] The objective of this study was to compare the efficacy of 10 mg Alfuzosin and 8 mg Silodosin in facilitating the passage of small ureteral stones (≤10 mm), with a focus on stone expulsion time. ...

Alfuzosin Stone Expulsion Therapy for Distal Ureteral Calculi: A Double-Blind, Placebo Controlled Study
  • Citing Article
  • June 2008

The Journal of Urology